Vyome Announces New Board of Directors with Deep MIT and AI Ties
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 12 2025
0mins
Source: Newsfilter
Vyome's Board Transition: Vyome Therapeutics, Inc. is set to take control of ReShape Lifesciences on August 15, 2025, with a new board comprised of experienced professionals, including MIT alumni, focused on aligning with shareholder interests and leveraging AI in healthcare.
Company Vision and Goals: Vyome aims to transform the lives of patients with immuno-inflammatory conditions while maintaining a cost-efficient operation and high standards of quality and safety, as it prepares for its public listing under the ticker 'HIND' following a reverse merger.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





